Breaks Categories: News

TuesdayFeb 21, 2023 12:44 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Findings from Hypertension Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is reporting additional findings from its human clinical study HYPER-H21-4; the study is designed to demonstrate a potentially novel mechanism of action of LEXX’s patented DehydraTECH-processed cannabidiol ("CBD") capsule formulation in the treatment of blood pressure ("BP"). According to the announcement, Lexaria believes that those findings, which were published in the peer-reviewed “Biomedicine and Pharmacotherapy" journal, could support DehydraTECH-CBD qualification within existing Food and Drug Administration (“FDA”) guidelines. Previous results of the study indicated that primary efficacy and safety objectives were successfully achieved, including hypertensive patients seeing resting blood pressure…

Continue Reading

TuesdayFeb 21, 2023 10:42 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q2 2023 Financial, Corporate Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, is reporting on its second quarter of fiscal year 2023, the period that ended Dec. 31, 2022. Highlights of the report include the company closing the calendar year with nearly $11.5 million in cash and the completion of enrollment in the company’s phase 2 clinical trial in epidermolysis bullosa (“EB”). The report also noted that the company has seen advancement in its research using rare cannabinoids in the treatment of glaucoma and neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s. “This…

Continue Reading

ThursdayFeb 16, 2023 2:11 pm

CannabisNewsBreaks – AmeriCann Inc. (ACAN) Releases Financial Results Showing Four Consecutive Quarters of Positive Net Income

AmeriCann (OTCQB: ACAN), a cannabis company that develops state-of-the-art cultivation, product manufacturing and distribution facilities, is reporting on its quarter ending December 2022; the report included both financial and operational highlights and noted that the company has seen four straight quarters of positive net income. Other financial highlights include the following: the company is seeing accelerating revenue, net income and adjusted operating EBITDA, which is driven by the performance of ACAN’s Massachusetts Cannabis Center (“MCC”); revenue for the quarter totaled $734,764, which was a 13% increase compared to the quarter ended December 2021; Adjusted EBITDA for the quarter increased by…

Continue Reading

ThursdayFeb 16, 2023 1:55 pm

CannabisNewsBreaks – ECGI Holdings Inc. (ECGI) Announces Planned Acquisition Representing ‘Plug-and-Play’ Access to Dynamic Market

ECGI Holdings (OTC: ECGI), D/B/A Elite Cannabis Group Incorporated, a Nevada-based portfolio company pivoting into the legal cannabis and cannabinoid marketplace, today announced its entry into a definitive agreement to acquire East West Pharma Group Inc. (“EWPG”), a Wyoming corporation with specialized equipment and experienced personnel, including leaders in the cannabinoid extraction and product manufacturing space. As previously announced, the acquisition represents a shift in the company’s strategy by becoming part of the $2.7 billion cannabis manufacturing, extract and concentrates marketplace. “Now that the agreement is in place, we are excited to hit the ground running,” said ECGI CEO Danny…

Continue Reading

WednesdayFeb 15, 2023 11:00 am

CannabisNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Releases Financial Report, Corporate Update for Q3

India Globalization Capital (NYSE American: IGC) (dba IGC Inc.) is reporting on its financial and corporate performance for the third fiscal quarter 2023. Highlights of the report include a focus on the company’s phase 2 clinical trial on IGC-AD1 for agitation in dementia from Alzheimer’s disease. The company reports that the number of sites participating in the trial has reached four: three sites in the United States and one site in Canada. In addition, based on patient enrollment and interest in the study, the company plans to more than double the number of trial sites, from the planned 4 or…

Continue Reading

WednesdayFeb 08, 2023 11:19 am

CannabisNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) to Be Featured in Radius Research Webinar

India Globalization Capital (NYSE American: IGC) today announced that its CEO Ram Mukunda and PFO Claudia Grimaldi will be featured in an investor webinar hosted by Radius Research. Beginning at 12:30 p.m. ET on Friday, Feb. 10, Mukunda and Grimaldi will discuss the company’s phase 2 trial for its drug candidate IGC-AD1 in treating agitation in dementia patients suffering from Alzheimer’s. They will also participate in a question-and-answer session. Interested parties should visit https://cnw.fm/sMqkJ to register for the webinar. To view the full press release, visit https://cnw.fm/6BD8E About India Globalization Capital Inc. IGC develops advanced cannabinoid-based formulations for treating diseases…

Continue Reading

MondayJan 30, 2023 10:30 am

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Issues 2023 Forecasted Revenue Anticipating >100% YOY Growth

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced revenue guidance of US$90 million to US$105 million for fiscal year 2023. Flora’s 2023 revenue guidance reflects expected organic growth in its House of Brands division and expansion of its Commercial & Wholesale division capabilities. In addition, the forecasted growth incorporates Flora’s new German-based business as established through the acquisition of Franchise Global Health. “We are pleased to announce that we will meet our guidance for 2022 and are issuing revenue guidance of $90 million - $105 million for the year 2023,”…

Continue Reading

FridayJan 27, 2023 11:25 am

CannabisNewsBreaks – IBN to Shine the Spotlight on 2023 Marquee Events for Cannabis Drinks Expo

IBN (“InvestorBrandNetwork”), a multifaceted communications organization with 50+ brands, today announced its re-engagement with Cannabis Drinks Expo to serve as an official media sponsor for its marquee exhibits in San Francisco and Chicago. The events, to be held later this year, will be organized by Beverage Trade Network and draw industry stalwarts, public policy experts and renowned innovators. As part of a larger multi-year series, they have grown to become the largest gathering of the cannabis drinks industry around the globe. In its capacity as the media sponsor, IBN will leverage its array of extensive corporate communications solutions to heighten…

Continue Reading

ThursdayJan 26, 2023 10:56 am

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces Year-End Webcast Review

Flora Growth (NASDAQ: FLGC), a leading outdoor grower, manufacturer and distributor of cannabis products and brands worldwide, has scheduled a webcast to provide an overview of the company’s operational milestones achieved in 2022. The year-end review is slated for Jan. 30, 2023, and will begin at 4:30 p.m. ET. The webinar, which will be prerecorded, will feature Flora Growth chair and CEO Luis Merchan, who will discuss the company’s 2022 operational performance; Merchan will also talk about the company’s 2023 revenue guidance. Those who attend the event will receive a recording of the webcast after it is concluded; a recording…

Continue Reading

MondayJan 23, 2023 1:30 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pharmaceutical Expert as New Strategic Advisor

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has a new strategic advisor. The company announced that Julian Gangolli, the former president of GW Pharmaceuticals USA, has joined Lexaria as a strategic advisor. During his time at GW Pharmaceuticals, Gangolli managed US Food and Drug Administration approval of Epidiolex(R), the only pure cannabidiol (“CBD”) drug ever approved by the agency; he also oversaw the commercialization of the drug in the United States, which ultimately led to Jazz Pharmaceuticals acquiring GW Pharmaceuticals in a $7.2 billion transaction. In addition to his work at GW Pharmaceuticals, Gangolli served as North…

Continue Reading